Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.45 |
| ▸ | HTR2C | P28335 | 7/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27414914 | 0.88 | MAPK1 (0.56) | ALDH1A1PLK1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL3260887 | 0.86 | BRD4 (0.47) | ALDH1A1PLK1NPSR1HPGDKDM4E | |
| SCHEMBL12514239 | 0.85 | NOTUM (0.39) | NOTUMALDH1A1PLK1HTR2AHTR2C | |
| SCHEMBL13977275 | 0.85 | NOTUM (0.53) | NOTUMALDH1A1HPGDKDM4EHTR2A | |
| SCHEMBL2215605 | 0.85 | NOTUM (0.53) | NOTUMALDH1A1HPGDKDM4EMYC | |
| SCHEMBL25260780 | 0.82 | SMN1; SMN2 (0.53) | NOTUMALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL2213963 | 0.81 | NPSR1 (0.70) | ALDH1A1NPSR1HPGDKMT2ATSHR | |
| SCHEMBL27562800 | 0.81 | NOTUM (0.47) | NOTUMALDH1A1PLK1NPSR1HPGD | |
| SCHEMBL2449412 | 0.79 | PLK1 (0.73) | NOTUMALDH1A1PLK1KDM4EMYC | |
| SCHEMBL2213168 | 0.79 | NPSR1 (0.60) | NOTUMALDH1A1NPSR1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| WO-2022047014-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2022-03-03 | — | — | WO | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | NOTUM 2246/4885ALDH1A1 464/4885PLK1 4298/4885 |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | NOTUM 2865/4885ALDH1A1 1721/4885PLK1 2501/4885 |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | NOTUM 2865/4885ALDH1A1 1721/4885PLK1 2501/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | NOTUM 2865/4885ALDH1A1 1721/4885PLK1 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.